With the recent availability of generic versions of semaglutide, an obesity treatment, Dr. Nikhil Tandon, an endocrinologist at the All-India Institute of Medical Sciences in Delhi, highlights the risks associated with its misuse for cosmetic weight loss. He describes the situation as a 'double-edged sword,' where improved access could lead to dangerous unsupervised use, particularly through online pharmacies. Tandon emphasizes that semaglutide should only be used under medical supervision due to its potential for serious side effects, including pancreatitis and acute kidney injury. He advocates for stricter enforcement of prescription regulations, especially in online settings, and stresses the need for ongoing lifestyle changes to ensure the drug's effectiveness. Long-term use of semaglutide poses additional risks, including gastrointestinal complications and potential eye issues, necessitating careful monitoring. Tandon concludes that patient safety relies on a collaborative approach involving regulatory measures, clinical responsibility, and increased public awareness.